#Ledipasvir 90 mg

[aprazerhealth]

Different treatment options for hepatitis C

Liver transplantation

When hepatitis C infection advances to chronic infection, the patient may develop serious complications, and in this situation, liver transplantation becomes the only effective treatment option. Your surgeon will remove your damaged organ during the liver transplantation process and will replace the liver with a healthy one. Most transplanted liver is received from deceased donors, and only a small number of transplanted livers come from living donors. Liver transplantation would not guarantee success and cure hepatitis C completely since the infection can return; therefore, antiviral medications like Ledipasvir 90 mg must be taken to eliminate damage to the newly transplanted liver. 

Antiviral medications

Hepatitis C can be treated with the help of antiviral medication, which clears the hepatitis C virus from your system. The main goal of these medications is to make the hepatitis C infection reach undetected levels in your body within twelve weeks after the treatment process. Today researchers have made great advances in diagnosis and treatment procedures for hepatitis C, and direct-acting antiviral medications have come up, such as sofosbuvir tablets 400 mg that is given to people along with a combination of the other existing medicines. This is why people have a better prognosis, short treatment time, and few side effects today. The length of the treatment process and dose of medications will depend on the extent of your liver damage, the genotype of hepatitis C that you have, the prior treatments, and your medical condition.

Vaccinations

There isn’t any vaccine available for hepatitis C; however, your physician will ask you to get a vaccination against hepatitis A and the hepatitis B virus. Both of these viruses can affect and damage your liver once your hepatitis C infection progress to the chronic stage.

Hepatitis C infection is a lifelong health condition for many people; however, as per studies, 50% of people get cleared of this virus without opting for any treatment. For others, this infection advances to the chronic stage. Most of them don’t seek treatment options since they are unaware of the presence of the hepatitis C virus in their system. It is only when the virus leads to chronic stage or serious consequences people get screened for this infection and seek medical care. The latest treatment options and medications for hep C, like ledikast tablet in pill form, has few side effects and better effect. These drugs have shown high rates of success in curing the infection. Hepatitis C is a serious infection that requires active treatment. As plenty of medication and treatment options are available, your doctor will aise you on the right treatment plan based on your circumstance and condition.

Direct-acting antiviral (DAA)

These medicines are the most effective and safest for treating hepatitis C infection. They have helped people clear of this infection in 90% of the cases. The length of the treatment option will depend mostly on the type of hepatitis infection you are having. DAA are an effective treatment option for hepatitis C; however, they have few side effects. Most people living with hepatitis find medications easy to take. It is important to complete the course of the medication to ensure that the virus is cleared from your body. Direct-acting antivirals have cured nine out of ten people with hepatitis C infection. Although successful treatment will not assure you complete protection against hepatitis C, you need to get screened to know whether you have got the infection again.

[rxmedicoss]

Ledifos (Ledipasvir & Sofosbuvir) | Generic Equivalant to Harvoni

Best anti cancer medicine in USA Best anti hiv medicine in USA Best hepatitis medicine in USA ibrance cost ibrance generic palbociclib cost in india palbociclib price in india lenalidomide 25 mg price in india revlimid generic cost Ibrance 125 mg price in india

$188.00

Essential Ingredient – Ledipasvir & Sofosbuvir

Product Name – Ledifos

Manufacturer – HETRO

Packing – Bank of 28 Tabs

Strenth in mg – 400/90 mg

Ledipasvir & Sofosbuvir combind combination is used to treat long lasting HEPATITIS C. Ledipasvir & Sofosbuvir combination is used to treat Adults and Children above 3 years of age, those who are suffering with CHRONIC HEPATITIS C.Ledipasvir & Sofosbuvir combination medications is also useful to those patients who are undergoing LIVER TRANSPLANTATION. The combination of two antiviral medicines (Ledipasvir & sofosbuvir ) workes by sloweing the amount of HEPATITIS C VIRUS in human body and over a period of tiome HEPATITIS C VIRUS completely exit the human body and improves the immune systum of the body.

[sunnyoharma]

Harvoni combines ledipasvir, an HCV NS5A inhibitor, and sofosbuvir, an HCV NS5B polymerase inhibitor. It could cause your hepatitis C virus more durable to treatment with anti-viral medicines . If you could have a hepatitis B infection, using sofosbuvir and velpatasvir may trigger the virus to become more lively and won't assist your EPCLUSA remedy at all or it could cause demise. Test all sufferers for proof of current or prior hepatitis B virus infection before initiating remedy with sofosbuvir / velpatasvir. HBV reactivation has been reported in HCV/HBV coinfected patients who have been undergoing or had accomplished therapy with HCV direct appearing antivirals and weren't receiving HBV antiviral therapy. Some circumstances have resulted in fulminant hepatitis, hepatic failure, and death. mavyret generic

Founded in 2018, Asegua Therapeutics LLC is committed to providing larger access to therapies. Asegua Therapeutics LLC has launched a licensed generic of EPCLUSA® (sofosbuvir/velpatasvir) and an authorized generic of HARVONI® (ledipasvir/sofosbuvir). There are not any enough, nicely-managed studies in pregnant women who've taken Epclusa without ribavirin. Epclusa must be used during being pregnant only if the potential benefit justifies the potential danger to the fetus.

Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV therapy and submit-remedy comply with-up. Initiate acceptable affected person administration for HBV an infection as clinically indicated. Similar data had been used to assist dosing recommendations for pediatric topics with HCV genotype 1, 2, 3, 4, 5 or 6 an infection who have extreme cirrhosis. Sofosbuvir/velpatasvir in combination with ribavirin is indicated for the therapy of kids six years and older or weighing a minimum of 37 kilos with severe cirrhosis. Sofosbuvir/velpatasvir, bought under the model name Epclusa among others, is a hard and fast-dose mixture medication for the treatment of hepatitis C in adults. It is greater than 90% effective for hepatitis C genotypes one via six. It also works for hepatitis C in those who even have cirrhosis or HIV/AIDS.

Tell your doctor about all your present medicines and any drugs you start or stop utilizing. If you have ever had hepatitis B, utilizing sofosbuvir and velpatasvir may cause this virus to become active or get worse. You might have frequent liver operate checks while using this medicine and for a number of months after you stop. In one aspect, the method contains administering to the topic an interferon-free therapy routine comprising an effective amount of GS-7977 and an efficient quantity of ribavirin. In a specific aspect, the method is sufficient to provide an undetectable quantity of HCV RNA in the topic for at least 12 weeks after the tip of the time interval. During pregnancy, this medication ought to be used solely when clearly needed. Sofosbuvir/velpatasvir, together with ribavirin, must not be used during being pregnant by both the pregnant lady or her male associate.

A licensed pharmacist is aware of how so you better ask for advice from them on the way to properly dispose of EPCLUSA. If vomiting happens within 3 hrs after taking EPCLUSA, take one other dose. If it is already longer than 3 hrs since you could have taken the first one, then don't take another pill of EPCLUSA. Just proceed with the conventional dosage and circulate of your therapy. In case you are taking Ribavirin additionally whereas under EPCLUSA prescription, then there is a treatment guide you should follow from your well being professional, and that includes how many doses you ought to be taking. The data offered in this web site is for educational purposes and not meant to exchange a discussion or recommendation with a healthcare supplier.

Common unwanted side effects embrace complications, feeling drained, bother sleeping, and nausea. It has not been studied in pregnant ladies or during breastfeeding. Greater care is required in those who are also infected with hepatitis B. Sofosbuvir works by blocking the NS5B protein and velpatasvir works by blocking the NS5A protein. One tablet as soon as day by day, often for 12 weeks, with or without food.

Read the Patient Information Leaflet if obtainable from your pharmacist before you begin taking sofosbuvir/velpatasvir and every time you get a refill. It isn't known if this remedy can stop you from passing the virus to others. Do not share needles, and apply "safer sex" to lower the risk of passing the virus to others. “We count on to see a positive impression on sharing Medicaid markets during the second half of 2019. One means Gilead's doing that's through state-managed Medicaid plans. When Gilead first unveiled the generics initiative, Evercore ISI analyst Umer Raffat famous the corporate’s presence in Medicaid was very low, as Mavyret takes the lion’s share.

In patients with serologic evidence of HBV an infection, monitor for scientific and laboratory signs of hepatitis flare or HBV reactivation during HCV remedy with EPCLUSA and through publish-treatment comply with-up. Hepatitis B virus reactivation has been reported in HCV/HBV coinfected patients who have been undergoing or had completed treatment with HCV direct appearing antivirals, and who weren't receiving HBV antiviral remedy. Cases have been reported in patients who're HBsAg positive and in addition in sufferers with serologic evidence of resolved HBV infection (i.e., HBsAg negative and anti-HBc constructive). HBV reactivation has also been reported in patients receiving sure immunosuppressants or chemotherapeutic agents; the danger of HBV reactivation associated with therapy with HCV direct-acting antivirals may be elevated in these patients. Increases in indirect bilirubin up to three mg/dL above baseline have been noted among HIV-1/HCV coinfected subjects handled with EPCLUSA and an atazanavir/ritonavir-primarily based antiretroviral regimen. The elevated indirect bilirubin values weren't associated with scientific antagonistic occasions, and all topics completed 12 weeks of EPCLUSA without dose adjustment or remedy interruption of both EPCLUSA or HIV antiretroviral agents. In the Phase three trial with decompensated cirrhosis (ASTRAL-four), isolated, asymptomatic creatine kinase elevations larger than or equal to 10xULN were reported in 1% of subjects treated with EPCLUSA with ribavirin for 12 weeks.

LEDIPASVIR/SOFOSBUVIR is a prescription medicine used to treat adults with chronic hepatitis C genotype 1, four, 5 or 6 infection with or with out cirrhosis . In these with GT 1 and superior cirrhosis or with GT 1 or four with or with out cirrhosis who've had a liver transplant, LEDIPASVIR/SOFOSBUVIR is used with ribavirin. SOFOSBUVIR/VELPATASVIR is a prescription drugs used to deal with adults with chronic hepatitis C genotype 1, 2, 3, four, 5, or 6 infection with or with out cirrhosis . In these with superior cirrhosis , SOFOSBUVIR/VELPATASVIR is used with ribavirin.

[anticancermedsrx1-blog]

Scorpion Healthcare Pharmacy is an online pharmacy store from where you can buy Hepcinat LP Tablets Online at the cheapest price for the effective treatment of chronic hepatitis C genotype infection.

[letrang39]

Thuốc Sofuled 90 mg/400 mg là thuốc kháng vi-rút tác dụng trực tiếp, điều trị viêm gan C mãn tính. Thuốc Sofuled chứa sự kết hợp của hai thành phần chính là 90mg Ledipasvir và 400mg Sofosbuvir có tác dụng ức chế, ngăn ngừa vi-rút phát triển và nhân lên trong cơ thể. Hiện nay, trên thị trường có rất nhiều loại thuốc điều trị viêm gan C. Tuy nhiên, mỗi bệnh nhân sẽ phù hợp với từng loại thuốc khác nhau. 

[greatestlcve]

Harvoni medication Uses, Dosage, Side Effects, Precautions & Warnings

Drug Online

Harvoni medication >>>  Generic drugof the Therapeutic class: Gastro-Entero-Hepatology active ingredients: Ledipasvir , Sofosbuvir

Important to know about harvoni medication ?

Sofosbuvir and ledipasvir inhibit the growth of hepatitis C virus.

In chronic hepatitis C (liver inflammation).

It takes several months until your symptoms decrease, such as fatigue and abdominal complaints.

A course usually lasts 12 to 24 weeks, sometimes 8 weeks is sufficient. Complete the entire course, even if your symptoms have already disappeared.

You may take the tablet with or without food. Swallow it whole, without chewing. The tablet tastes otherwise very bitter.

Are you nauseous and do you have to vomit? If you have to vomit within 5 hours after swallowing this medicine, you must take a new tablet. Otherwise, it does not work properly.

Side effects may include headache, fatigue, skin rash and hypersensitivity.

There are many interactions with other means. Have your pharmacist check whether you can use it safely with your other medicines, even those that you have bought without a prescription.

what is harvoni used to treat and indication?

Harvoni is indicated for the treatment of chronic hepatitis C (CHC) in adults   (see sections Dosage and Administration , Warnings and Precautions and Pharmacodynamic properties ).

For activity based on hepatitis C virus (HCV) genotype, see Warnings and Precautions andPharmacodynamic Properties sections .

Harvoni Dosage

Dosage

The recommended dose is one Harvoni tablet once a day, with or without food (see section Pharmacokinetic properties ).

<brarial’,’sans-serif’; color:=”” black”=””>Table 1: Recommended duration of treatment with Harvoni and recommendations for co-administration with ribavirin in certain subgroups</brarial’,’sans-serif’;>

Patient population *TreatmentDurationPatients with genotype 1 or genotype 4 HCC12 weeks.

– A duration of 8 weeks could be considered in patients infected with genotype 1 not previously treated (see section <iarial’,’sans-serif’; color:=”” black”=””>Pharmacodynamic properties, ION-3 study).</iarial’,’sans-serif’;>

Patients without cirrhosisHarvoni– A duration of 24 weeks should be considered in previously treated patients for whom the possibilities of subsequent re-treatment are uncertain (see section Warnings and precautions for use ).Patients with compensated cirrhosisHarvoni24 weeks.

– A duration of 12 weeks could be considered in patients for whom the risk of clinical progression of the disease is considered low and for whom subsequent retreatment options exist (see section 4.4 ).

Patients with decompensated cirrhosis or in a pre / post liver transplant situationHarvoni + ribavirin24 weeks (see warnings and precautions for use and Pharmacodynamic properties )Patients with genotype 3 CHCPatients with cirrhosis and / or failure of a previous treatmentHarvoni + ribavirin24 weeks (see warnings and precautions for use and Pharmacodynamic properties )

* Includes patients co-infected with human immunodeficiency virus (HIV).

If used in combination with ribavirin, see also the Summary of Product Characteristics for ribavirin.

In patients without decompensated cirrhosis and requiring the addition of ribavirin in their treatment (see table 1), the daily dose of ribavirin is calculated according to the weight (<75 kg = 1000 mg and ≥ 75 kg = 1 200 mg) and is administered orally in two divided doses, with food.

In patients with decompensated cirrhosis, ribavirin should be administered at the starting dose of 600 mg divided over the day. If the initial dose is well tolerated, the dose may be increased gradually to a maximum of 1000-1200 mg per day (1000 mg for patients weighing <75 kg and 1200 mg for patients weighing ≥ 75 kg ).

 If the initial dose is not well tolerated, the dose should be reduced as needed based on hemoglobin levels.

Dose modification of ribavirin in patients taking 1,000-1,200 mg per day

If Harvoni is used in combination with ribavirin and a patient experiences a serious side effect potentially related to ribavirin, the dose of ribavirin should be changed or the treatment stopped, if necessary, until the side effect disappears or its severity decreases. Table 2 gives the recommendations for dose modification and discontinuation of treatment depending on the hemoglobin concentration and the patient’s heart condition.

Table 2: Recommendations for dose modification of ribavirin co-administered with Harvoni

Biological valuesReduce the ribavirin dose to 600 mg / day if:Stop ribavirin if:Hemoglobin levels in patients without heart disease<10 g / dL<8.5 g / dLHemoglobin level in patients with a history of stable heart diseaseDecrease in hemoglobin ≥ 2 g / dL during a 4 week treatment period<12 g / dL despite taking a reduced dose for 4 weeks

When ribavirin has been discontinued due to a biological defect or clinical manifestation, an attempt may be made to re-initiate ribavirin at a dose of 600 mg per day and then increase further. the dose up to 800 mg per day. However, increasing ribavirin to the dose initially prescribed (1000 mg to 1200 mg per day) is not recommended.

Patients should be informed that if they vomit within 5 hours of taking their dose, they should take another tablet. If they vomit more than 5 hours after taking their dose, it is not necessary to take another dose.

Patients should be informed that if they forget to take a dose and they notice it within 18 hours of their usual dose, they should take the tablet as soon as possible and then take the next dose as scheduled . If they find out more than 18 hours later, they should wait and take the next dose as scheduled. Patients should be instructed not to take a double dose.

The elderly

No dose adjustment is necessary in elderly patients (see section Pharmacokinetic properties ).

Renal failure

No dose adjustment of Harvoni is necessary in patients with mild or moderate renal impairment. The safety of ledipasvir / sofosbuvir has not been evaluated in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] <30 mL / min / 1.73 m 2 ) or d end-stage renal disease (ESRD) requiring hemodialysis.

Hepatic insufficiency

No dose adjustment of Harvoni is necessary in patients with mild, moderate or severe hepatic impairment (Child-Pugh-Turcotte score [CPT] A, B or C) (see section Pharmacokinetic properties ). The safety and efficacy of the ledipasvir / sofosbuvir combination have been established in patients with decompensated cirrhosis (see section Pharmacodynamic properties ).

Pediatric population

The safety and efficacy of Harvoni in children and adolescents under 18 years of age have not been yet been established. No data is available.

Administration mode

Oral use.

Patients should be informed that they should swallow the tablet whole, with or without food. Due to its bitter taste, it is recommended not to chew or crush the film-coated tablet .

what’s Contraindications for

harvoni?

Hypersensitivity to the active ingredients or to any of the excipients listed in the Composition section .

Co-administration with rosuvastatin or St. John’s wort ( Hypericum perforatum ) (see section Interactions with other medicinal products and other forms of interaction ).

harvoni how does it work?

Absorption

After oral administration of ledipasvir / sofosbuvir in HCV infected patients, the median peak plasma concentration of ledipasvir was reached 4.0 hours after dosing. Sofosbuvir was rapidly absorbed and the median plasma peaks were reached ~ 1 hour after dosing.

The median plasma peak of GS-331007 was reached 4 hours after

administration.

Based on population pharmacokinetic analysis in HCV-infected patients, geometric means of steady-state AUC 0-24 for ledipasvir (n = 2,113), sofosbuvir (n = 1,542) and GS-331007 (n = 2,113) were 7,290, 1,320 and 12,000 ng • h / mL, respectively. The steady-state C max for ledipasvir, sofosbuvir, and GS-331007 were 323, 618 and 707 ng / mL, respectively. The AUC 0-24 and C max of sofosbuvir and GS-331007 were similar in healthy adult volunteers and in patients infected with HCV.

Compared to healthy subjects (n = 191), AUC 0-24 and C maxof ledipasvir were 24% and 32% lower, respectively, in HCV-infected patients. The AUC of ledipasvir is dose proportional over a dose range of 3 to 100 mg.

The AUCs of sofosbuvir and GS-331007 are quasi-dose-proportional over a dose range of 200 mg to 400 mg.

Effects of food intake

Compared with fasting, administration of a single dose of ledipasvir / sofosbuvir with a moderate or high fat meal increased the 0-inf AUC of sofosbuvir by approximately 2-fold. but did not significantly change sofosbuvir C max .

Exposures to GS-331007 and ledipasvir were not affected by these two types of meals. Harvoni can be administered with or without food.

Distribution

The binding of ledipasvir to human plasma proteins is> 99.8%. After administration of a single 90 mg dose of [ 14 C] -ledipasvir in healthy subjects, the blood / plasma radioactivity ratio [ 14 C] was between 0.51 and 0.66.

The binding of sofosbuvir to human plasma proteins is approximately 61 to 65% and the binding is independent of the concentration of the product, in the range of 1 to 20 µg / mL. The binding of GS-331007 to proteins is minimal in human plasma. Following a single 400 mg dose of [ 14 C] -sofosbuvir in healthy subjects, the ratio of blood [ 14 C] to plasma radioactivity was approximately 0.7.

Biotransformation

In vitro, no detectable metabolism of ledipasvir by human CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 has been observed. Evidence of slow oxidative metabolism, the mechanism of which is not known, has been observed. After administration of a single 90 mg dose of [ 14 C] -ledipasvir, systemic exposure was almost exclusively due to the parent drug (> 98%). Unchanged ledipasvir is also the main form found in faeces.

Sofosbuvir is extensively metabolized in the liver to form the pharmacologically active nucleoside triphosphate analog GS-461203. The active metabolite is not detected. The metabolic activation pathway involves sequential hydrolysis of the carboxyl ester group, catalyzed by human cathepsin A or carboxyl esterase 1, and phosphoramidate cleavage by the HINT1 protein (histidine triad nucleotide-binding protein) followed by phosphorylation by the pyrimidine-nucleotide biosynthesis pathway. Dephosphorylation results in the formation of the nucleoside metabolite GS-331007, which cannot be re-phosphorylated effectively and which lacks anti-HCV activity in vitro. In the case of the ledipasvir / sofosbuvir combination, GS-331007 represents approximately 85% of the

Elimination

After a single 90 mg oral dose of [ 14 C] -ledipasvir, the average total recovery of radioactivity [ 14 C] in faeces and urine was 87%, with most of the radioactivity was recovered in faeces (86%). Unchanged ledipasvir excreted in the faeces averaged 70% of the administered dose and the oxidative metabolite M19 represented 2.2% of the dose. These data suggest that the primary route of elimination for unchanged ledipasvir is biliary excretion, with renal excretion being a minor route (approximately 1%). The median terminal half-life of ledipasvir in healthy volunteers following administration of ledipasvir / sofosbuvir on an empty stomach was 47 hours.

After administration of a single 400 mg oral dose of [ 14 C] -sofosbuvir the mean total dose recovery was greater than 92%, of which approximately 80%, 14% and 2.5% recovered in the urine. faeces and exhaled air, respectively. The majority of the sofosbuvir dose recovered in the urine was GS-331007 (78%) and 3.5% was sofosbuvir. These data show that renal clearance is the primary route of elimination for GS-331007 with a large proportion actively excreted. The median terminal half-lives of sofosbuvir and GS-331007 after administration of ledipasvir / sofosbuvir were 0.5 and 27 hours, respectively.

Neither ledipasvir nor sofosbuvir are substrates for active hepatic transporters, organic cation transporter (OCT) 1, organic anion transporting polypeptide (OATP) 1B1 or OATP1B3. GS-331007 is not a substrate for renal transporters, including organic anion transporter (OAT) 1 or OAT3, or OCT2.

Potential in vitro effect of ledipasvir / sofosbuvir on other medicinal products At concentrations achieved in clinical practice, ledipasvir is not an inhibitor of hepatic transporters, including OATP 1B1 or 1B3, BSEP, OCT1 , OCT2, OAT1, OAT3, the transporter MATE (mutidrug and toxic compound extrusion) 1, the multidrug resistance protein (MRP) 2 or the MRP4. Sofosbuvir and GS-331007 are not inhibitors of the drug transporters P-gp, BCRP, MRP2, BSEP, OATP1B1, OATP1B3 and OCT1, and GS-331007 is not an inhibitor of OAT1, ‘OCT2 and MATE1.

Sofosbuvir and GS-331007 are not inhibitors or inducers of CYP or uridine diphosphate glucuronosyltransferase (UGT) 1A1 enzymes.

Pharmacokinetics in special populations

Ethnicity and gender

No clinically significant pharmacokinetic differences due to ethnicity were noted for ledipasvir, sofosbuvir or GS-331007. No clinically significant pharmacokinetic differences due to gender were noted for sofosbuvir or GS-331007. The AUC and C max of ledipasvir were 77% and 58% higher, respectively, in women compared to men. However, the relationship between gender and ledipasvir exposures was not considered clinically relevant.

The elderly

Pharmacokinetic analysis of HCV-infected patient populations showed that, in the age range analyzed (18-80 years), age has no clinically significant effect on exposure to ledipasvir, sofosbuvir or GS-331007. The clinical studies of ledipasvir / sofosbuvir included 117 patients aged 65 years and over.

Renal failure

The pharmacokinetics of ledipasvir have been studied with a single 90 mg dose of ledipasvir in non-HCV infected patients with severe renal impairment (eGFR <30 mL / min by Cockcroft-Gault formula, median CrCl [limits] of 22 [17-29] mL / min). The pharmacokinetics of ledipasvir did not show any clinically significant difference between healthy subjects and patients with severe renal impairment.

The pharmacokinetics of sofosbuvir have been studied in non-HCV-infected patients with mild (eGFR ≥ 50 and <80 mL / min / 1.73m 2 ), moderate (eGFR ≥ 30 and <50 mL / min / renal impairment ). 1.73 m 2 ), severe (eGFR <30 mL / min / 1.73 m 2 ) and in patients with ESRD requiring hemodialysis, after a single 400 mg dose of sofosbuvir. Compared with patients with normal renal function (eGFR> 80 mL / min / 1.73 m 2 ), the 0-inf AUC of sofosbuvir was 61%, 107% and 171% higher in mild renal impairment. moderate and severe, while AUC 0-infof GS-331007 was 55%, 88% and 451% higher, respectively. In patients with ESRD compared to patients with normal renal function, the AUC 0-inf of sofosbuvir was 28% higher when sofosbuvir was given 1 hour before hemodialysis, compared to 60% higher when sofosbuvir was given 1 hour after hemodialysis. ASC 0-infof GS-331007 in patients with ESRD who received sofosbuvir one hour before or one hour after hemodialysis was at least 10 and 20 times higher, respectively. GS-331007 is effectively removed by hemodialysis, with an extraction coefficient of approximately 53%. Following a single 400 mg dose of sofosbuvir, a 4 hour hemodialysis removed 18% of the administered sofosbuvir dose. The safety and efficacy of sofosbuvir have not been established in patients with severe renal impairment or ESRD.

Hepatic insufficiency

The pharmacokinetics of ledipasvir have been studied with a single 90 mg dose of ledipasvir in non-HCV patients with severe hepatic impairment (CPT C score). Plasma exposure to ledipasvir (AUC inf ) was similar in patients with severe hepatic impairment and in control patients with normal hepatic function. Pharmacokinetic analysis of HCV-infected patient populations showed that cirrhosis has no clinically significant effect on exposure to ledipasvir.

The pharmacokinetics of sofosbuvir were studied after 7 days of administration of 400 mg / day of sofosbuvir in HCV-infected patients with moderate or severe hepatic impairment (CPT scores B and C). Compared to patients with normal hepatic function, the AUC 0-24 of sofosbuvir was 126% and 143% higher, respectively, in moderate or severe hepatic impairment, while the AUC 0-24 of GS-331007 was 18% and 9% respectively higher. Population pharmacokinetic analysis in HCV infected patients has shown that cirrhosis has no clinically significant effect on exposure to sofosbuvir and GS-331007.

Body weight

Body weight had no significant effect on exposure to sofosbuvir based on population pharmacokinetic analysis. Exposure to ledipasvir decreases with increased body weight, but this effect is not considered clinically significant.

Pediatric population

The pharmacokinetics of ledipasvir, sofosbuvir and GS-331007 have not been established in children.

(see section Dosage and method of administration ).

harvoni treatment side effects

In addition to the desired effect, this can cause drug side effects.

The main side effects are the following.

Sometimes (from 10 to 30 people in 100)

Headache , fatigue.

Rarely (from 1 to 10 in 100 people)

Skin rash . Contact your doctor if you notice this.

Very rare (affects less than 1 in 100 people)

Hypersensitivity to this medication. This can be expressed in ‘angioedema’: a swelling of the face, lips, mouth, tongue or throat. You can be very stuffy. If it occurs, you should immediately seek out a doctor or go to the First Aid Service. You can not use this type of medication in the future. Therefore tell the pharmacy that you are hypersensitive to this sofosbuvir with ledipasvir. The pharmacy team can then ensure that you do not get this medication again.

Consult your doctor if you suffer too much from one of the above mentioned side effects or if you experience other side effects that you are worried about.

harvoni interactions

Harvoni containing ledipasvir and sofosbuvir, all the interactions that have been observed with these active ingredients used individually can occur with Harvoni.

Potential effect of Harvoni on other drugs

Ledipasvir is an in vitro inhibitor of the P-gp drug transporter and Breast Cancer Resistance Protein (BCRP) protein and may increase the intestinal absorption of substrates from these transporters in case of co-infection. administration. In vitro data indicate that ledipasvir may be a weak inducer of metabolic enzymes such as CYP3A4, CYP2C and UGT1A1. Plasma concentrations of the compounds that are substrates of these enzymes could be reduced when co-administered with the ledipasvir / sofosbuvir combination. In vitro, ledipasvir inhibits intestinal CYP3A4 and UGT1A1. Drugs with a narrow therapeutic range and metabolized by these isoenzymes should be used with caution and under close supervision.

Potential effect of other drugs on Harvoni

Ledipasvir and sofosbuvir are substrates of the P-gp drug carrier and BCRP, whereas GS-331007 is not.

Drugs that are potent inducers of P-gp (rifampicin, rifabutin, St. John’s wort, carbamazepine, phenobarbital and phenytoin) can significantly decrease plasma concentrations of ledipasvir and sofosbuvir, reducing the therapeutic effect the ledipasvir / sofosbuvir association and therefore they are against-marked Harvoni (see Contraindications ). Drugs that are moderate inducers of P-gp in the gut (such as oxcarbazepine) may decrease plasma concentrations of ledispavir and sofosbuvir, reducing the therapeutic effect of Harvoni. Co-administration of this type of medication with Harvoni is not recommended (see section Warnings and Precautions section).). Co-administration of drugs that inhibit P-gp and / or BCRP may increase the plasma concentrations of ledipasvir and sofosbuvir without increasing that of GS-331007; Harvoni may be co-administered with inhibitors of P-gp and / or BCRP. No clinically significant effect on the ledipasvir / sofosbuvir combination is expected via CYP450 or UGT1A1 enzymes.

Patients treated with vitamin K antagonists

Because hepatic function may change during treatment with Harvoni, close monitoring of International Normalized Index (INR) values ​​is recommended.

Interactions between Harvoni and other drugs

Table 3 provides a list of clinically established or potentially clinically significant drug interactions (where the 90% confidence interval [IC] of the mean geometric least squares ratio [GLSM] was within the “↔” limits, in excess of “↑ “, Or lower than” ↓ “predetermined equivalence limits). The drug interactions described are based on studies conducted either with the combination of ledipasvir / sofosbuvir or with ledipasvir and sofosbuvir taken individually, or are predictions of drug interactions that may occur with the combination of ledipasvir / sofosbuvir. This table is not exhaustive.

Harvoni Warnings and Precautions :

Harvoni should not be administered at the same time as other medicines containing sofosbuvir.

Activity according to genotype

For recommended treatments for different genotypes of HCV, see Dosage and Method of Administration . For virologic and clinical activity by genotype, see the topic Pharmacodynamic properties .

Clinical evidence supporting the use of Harvoni in patients with HCV genotype 3 is limited . The relative efficacy of 12-week treatment with ledipasvir / sofosbuvir + ribavirin compared to a 24-week course with sofosbuvir + ribavirin, has not been studied. A conservative treatment of 24 weeks is recommended in all previously treated genotype 3 patients and in patients who are naive to any treatment with cirrhosis (see Dosage and method of administration section ).

Clinical evidence supporting the use of Harvoni in patients with HCV genotype 2 and 6 is limited.

Severe Bradycardia and Conduction Disorders

Cases of severe bradycardia and conduction disturbances have been observed with Harvoni when co-administered with amiodarone with or without other heart rate-lowering drugs. The mechanism is not established.

The concomitant use of amiodarone has been limited in the clinical development of sofosbuvir in combination with direct-acting antivirals (DAAs). Some cases have been life-threatening. Therefore, amiodarone should be used in patients treated with Harvoni only in case of intolerance or contraindication to other anti-arrhythmic treatments.

If concomitant use of amiodarone is considered necessary, close monitoring of patients is recommended when initiating Harvoni treatment. Patients identified as being at high risk for bradyarrhythmia should be monitored continuously for 48 hours in an adapted hospital environment.

Given the long half-life of amiodarone, appropriate monitoring should also be performed in patients who have discontinued amiodarone in recent months and need to start treatment with Harvoni.

All patients treated with Harvoni who receive amiodarone with or without other bradycardic medications should also be advised of symptoms of bradycardia and conduction disturbances, and should be informed of the need for urgent medical attention. feel these symptoms.

Treatment of patients previously treated with direct-acting antivirals for HCV In patients who have failed treatment with ledipasvir / sofosbuvir, a selection of resistance mutations in NS5A significantly reduces susceptibility to ledipasvir.

majority of cases (see section 5.1).). Limited data indicates that this type of mutation in NS5A is not reversible at long-term follow-up. In patients who have failed prior therapy with ledipasvir / sofosbuvir, there is currently no evidence to support the efficacy of re-treatment with NS5A inhibitor therapy. Similarly, in patients who have failed previous treatment with an NS3 / 4A protease inhibitor, there are currently no data supporting the efficacy of NS3 / 4A protease inhibitors. In these patients, the treatment of HCV infection may therefore depend on the use of other classes of drugs. Therefore, it will be necessary to

Renal failure

No dose adjustment of Harvoni is required in patients with mild or moderate renal impairment. The safety of Harvoni has not been evaluated in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] <30 mL / min / 1.73 m 2 ) or end-stage renal disease (IRT) requiring hemodialysis. If Harvoni is used in combination with ribavirin, also refer to the Summary of Product Characteristics of Ribavirin for patients with creatinine clearance (CrCl) <50 mL / min (see section 5.2 ).

Patients with decompensated cirrhosis and / or waiting for liver transplantation or post-liver transplantation

The efficacy of ledipasvir / sofosbuvir in patients with genotype 5 or genotype 6 HCV with decompensated cirrhosis and / or awaiting liver transplantation or post-liver transplantation has not been studied. The Harvoni treatment decision should be based on an assessment of the potential benefits and risks for each patient.

Use with moderate inducers of P-gp

Drugs that are moderate inducers of P-gp in the intestine (such as oxcarbazepine) may decrease the plasma concentrations of ledipasvir and sofosbuvir, reducing the therapeutic effect of Harvoni. Co-administration of this type of medication with Harvoni is not recommended (see section Interactions with other medicinal products and other forms of interaction ).

Use with some antiretrovirals for HIV

Harvoni has been shown to increase the exposure to tenofovir, particularly when used in combination with an HIV treatment containing tenofovir disoproxil fumarate and a pharmacokinetic booster (ritonavir or cobicistat). The safety of tenofovir disoproxil fumarate in the context of Harvoni treatment in the presence of a pharmacokinetic booster has not been established. The potential risks and benefits associated with co-administration of Harvoni with the fixed-dose combination tablet containing elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil fumarate or tenofovir disoproxil fumarate used in combination with a protease inhibitor Boosted HIV (eg atazanavir or darunavir) should be considered, especially in patients at increased risk of renal dysfunction. In patients receiving concomitant Harvoni with elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil fumarate or with tenofovir disoproxil fumarate and a boosted HIV protease inhibitor, undesirable effects associated with tenofovir should be monitored. See the Summary of Product Characteristics for tenofovir disoproxil fumarate, emtricitabine / tenofovir disoproxil fumarate, or elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil fumarate for recommendations for monitoring renal function. elventegravir / cobicistat / emtricitabine / tenofovir disoproxil fumarate or with tenofovir disoproxil fumarate and a boosted HIV protease inhibitor, undesirable effects associated with tenofovir should be monitored. See the Summary of Product Characteristics for tenofovir disoproxil fumarate, emtricitabine / tenofovir disoproxil fumarate, or elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil fumarate for recommendations for monitoring renal function. elventegravir / cobicistat / emtricitabine / tenofovir disoproxil fumarate or with tenofovir disoproxil fumarate and a boosted HIV protease inhibitor, undesirable effects associated with tenofovir should be monitored. See the Summary of Product Characteristics for tenofovir disoproxil fumarate, emtricitabine / tenofovir disoproxil fumarate, or elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil fumarate for recommendations for monitoring renal function.

Use with HMG-CoA reductase inhibitors

Co-administration of Harvoni with HMG-CoA reductase inhibitors (statins) can significantly increase the statin concentration, increasing the risk of myopathy and rhabdomyolysis (see section 4.5). forms of interactions ).

HCV / HBV co-infection (hepatitis B virus)

Cases of hepatitis B virus (HBV) reactivation, some with fatal outcome, have been reported during or after treatment with direct-acting antiviral agents. HBV testing should be performed in all patients prior to initiation of treatment. Patients co-infected with HBV / HCV are at risk for reactivation of HBV and should therefore be monitored and managed according to clinical guidelines.

Pediatric population

Harvoni is not recommended for use in children and adolescents under 18 years of age as the safety and efficacy of this medication have not been established in this population.

excipients

Harvoni contains an azo dye, S Yellow Orange Lake (E110), which can cause allergic reactions. It also contains lactose. As a result, patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose / galactose malabsorption should not take this medicine.

Drive and use machines

Harvoni (alone or in combination with ribavirin) has no or negligible effect on the ability to drive and use machines.

However, patients should be informed that fatigue was more common in patients treated with ledipasvir / sofosbuvir than in those receiving placebo.

Harvoni and PREGNANCY / BREAST FEEDING / FERTILITY

Women of childbearing

potential / contraception in men and women When Harvoni is used in combination with ribavirin, all precautions should be taken to prevent pregnancy in patients and female partners of patients. Significant teratogenic and / or embryocidal effects have been demonstrated in all animal species exposed to ribavirin. Women of childbearing potential or their male partners should use an effective method of contraception during treatment and for some time after the end of treatment, as recommended in the Summary of Product Characteristics of Ribavirin. 

See the Summary of Product Characteristics of Ribavirin for more information.

Pregnancy

There are no data or limited data (less than 300 pregnancies) on the use of ledipasvir, sofosbuvir or Harvoni in pregnant women.Studies in animals have not shown any direct deleterious effects on reproduction. No significant effects on fetal development were observed in rats and rabbits with ledipasvir or sofosbuvir. However, it was not possible to completely evaluate margins of exposure with sofosbuvir in rats in relation to human exposure at the recommended clinical dose.

As a precaution, it is best to avoid the use of Harvoni during pregnancy.

feeding

It is not known whether ledipasvir or sofosbuvir and their metabolites are excreted in breast milk.The pharmacokinetic data available in animals have demonstrated the excretion of ledipasvir and metabolites of sofosbuvir in milk 

A risk for newborns / infants can not be ruled out. Therefore, Harvoni should not be used while breastfeeding.

Fertility

There is no data on the effect of Harvoni on human fertility. Studies in animals have not shown deleterious effects of ledipasvir or sofosbuvir on fertility.

If ribavirin is co-administered with Harvoni, contraindications for the use of ribavirin during pregnancy and lactation apply (see also Summary of Product Characteristics of Ribavirin).

What should I do if I miss a dose?

It is important to take this medicine consistently. If you have forgotten a dose:

You use this medicine once a day:

Does it take more than 6 hours before you should take the next dose? Swallow the forgotten tablet as soon as

possible and take the next dose at the usual time.

Does it take less than 6 hours before you should take the next dose? Skip the forgotten tablet and take the next dose at the usual time.

What happens if I overdose from Harvoni ?

The highest documented doses of ledipasvir and sofosbuvir were 120 mg twice daily for 10 days and 1200 mg once, respectively. In these studies in healthy volunteers, no adverse events were observed at these doses and the adverse effects were similar in frequency and intensity to those reported in the placebo groups. The effects of higher doses are not known.

There is no specific antidote for overdose of Harvoni. If overdose occurs, all symptoms of toxicity will be monitored in the patient. Treatment of Harvoni overdose consists of general supportive measures, with monitoring of vital signs and observation of the patient’s clinical condition. It is unlikely that hemodialysis will significantly eliminate ledipasvir since ledipasvir is highly bound to plasma proteins. Hemodialysis can effectively remove the main circulating metabolite of sofosbuvir (ie GS-331007), with a 53% extraction ratio.

What is  Forms and Composition Harvoni?

90 mg / 400 mg film-coated tablet (diamond shaped, orange, size 19 mm × 10 mm, on one side with “GSI” inscription and on the other side “7985”):  Bottle of 28, with child safety closure system.

NOT’s

Edrug-online contains comprehensive and detailed information about drugs available in the medical field, and is divided into four sections:

general information:

Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

Additional information:

General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

Special warnings:

For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

Side effects:

It treats possible side effects and drug interactions that require attention and its effect on continuous use.

The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

The post Harvoni medication Uses, Dosage, Side Effects, Precautions & Warnings appeared first on Drug Online.

from Drug Online https://bit.ly/3eY6utB via Edrug Online from Faculty of Medicine https://bit.ly/2Dbn103 via Internal Medicine

[miajenniblr-blog]

Hepcinat LP in romania - Generico Harvoni Prospect, Forum, efecte secundare, Pret india.

Cumpara Hepcinat LP ( Ledipasvir/Sofosbuvir) Generic Harvoni comprimate sunt utilizate pentru tratamentul hepatitei c Genotipul 1 infectie.MillionPharma a oferit Natco droguri cel mai bun pret din romania.

Jessey Ka's insight:

Combinația sa de Sofosbuvir 400 mg și Ledipasvir 90 mg a fost creată special pentru tratamentul genotipului hepatitei C genotipului 1-4. Acest medicament Natco are, de asemenea, efecte similare cu HARVONI în tratarea hepatitei cronice C (CHC).

[hepatita-c-romania-blog]

Ledifos-tablete-pret-India

Ledifos in Romania :

Ledifos este o altă versiune generică a lui Harvoni.

Creat de India de Hetero Labs, a fost lansat în 2015.

Costul Ledifos din India a redus suplimentar prețurile la medicamentele pentru hepatita C

Ledifos de Hetero :

Ledifos Tabletele de 90 mg ledipasvir / 400 mg de sofosbuvir au fost dezvoltate și introduse pe piață de o companie indiană Hetero Labs.

Hetero Labs este una…

[rxmedicoss]

LediHep (Ledipasvir & Sofosbuvir) | Generic Equivalant to Harvoni

Best anti cancer medicine in USA Best anti hiv medicine in USA Best hepatitis medicine in USA ibrance cost ibrance generic palbociclib cost in india palbociclib price in india lenalidomide 25 mg price in india revlimid generic cost Ibrance 125 mg price in india

 $244.00

Essential Ingredient – Ledipasvir & Sofosbuvir

Product Name – LediHep

Manufacturer – ZYDUS

Packing – Bank of 28 Tabs

Strenth in mg – 400/90 mg.

Ledipasvir & Sofosbuvir combind combination is used to treat long lasting HEPATITIS C. Ledipasvir & Sofosbuvir combination is used to treat Adults and Children above 3 years of age, those who are suffering with CHRONIC HEPATITIS C. Ledipasvir & Sofosbuvir combination medications is also useful to those patients who are undergoing LIVER TRANSPLANTATION. The combination of two antiviral medicines (Ledipasvir & sofosbuvir ) workes by sloweing the amount of HEPATITIS C VIRUS in human body and over a period of tiome HEPATITIS C VIRUS completely exit the human body and improves the immune systum of the body.

[harvoni2-blog]

BonHoa Pharmacy is one of the biggest generic hepatitis and cancer drug store in the world and the biggest online pharmacy in India. We sell cancer drugs to people more than 150 countries all over the world.

[anticancermedsrx1-blog]

Scorpion Healthcare Pharmacy offers you to buy Ledifos 90Mg/400Mg Tablets Online at the very cheapest price. Order Ledipasvir 90 mg & Sofosbuvir 400 mg Tablets for the effective treatment of chronic hepatitis C genotype infection.

[gotoocollectorheart-blog]

Cimivir L

Buy  Online Cimivir L Tablet : Uses, Price, Side Effects, Composition, Substitutes

Know Cimivir L Tablet uses, side-effects, composition, substitutes, drug interactions, precautions, dosage, and warnings only on mymedistore.com. Cimivir L is a fixed-dose combination tablet containing Ledipasvir 90mg and Sofosbuvir 400 mg for oral administration used with or without ribavirin for the treatment of chronic (lasting a long time) hepatitis C virus (HCV) genotype 1, 4, 5 or 6 infection.

Uses Cimivir L is a prescription medicine used with or without ribavirin for the treatment of chronic (lasting a long time) hepatitis C virus (HCV) genotype 1, 4, 5 or 6 infection. Introduction Cimivir L is a fixed-dose combination tablet containing Ledipasvir and Sofosbuvir Tablets for oral administration. Ledipasvir is an HCV NS5A inhibitor and sofosbuvir is a nucleotide analog inhibitor of HCV NS5B polymerase. Each tablet contains ledipasvir 90 mg and sofosbuvir 400 mg. How Cimivir L (Ledipasvir And Sofosbuvir Tablets) Works? Ledipasvir inhibits the HCV NS5A protein, which is required for viral replication. Sofosbuvir inhibits HCV NS5B RNA-dependent RNA polymerase, which is required for viral replication. Dosage & Administration Cimivir L is to be administered under the strict supervision of a Hepatologist only. An extra patient leaflet is available with Ledipasvir and Sofosbuvir Tablets. Talk to your pharmacist if you have questions about this information. Cimivir L is to be taken by adults over 18 years of age only. Cimivir L is to be taken orally with a full glass of water. Cimivir L Can be tacken with or without food. The maximum recommended dosing frequency is once per day. To be taken at the same time every day (24 hour gap). Cimivir L’s length of treatment may vary for a period between 8 weeks to 24 weeks. Do not stop use and intake of other anti-viral medications alongside Cimivir L unless instructed by your doctor. Important – The correct dosage and prescription commonly depend on the patient and the condition being treated. Duration of dosage can range between 8 weeks to 24 weeks and the correct duration of treatment is to be determined by your medical practitioner or doctor as it will depend on the patient’s condition and their response to the therapy. Do not adjust your dosage without the approval of your medical practitioner or doctor. This product is only for use as prescribed and instructed by a doctor or medical practitioner. Contradictions & Warnings Cimivir L is not always suitable for all patients. Do not take Cimivir L as it is contradicted in the following known cases: Pregnancy / Breast Feeding – Do not use this medicine if you are pregnant or breastfeeding or trying to get pregnant. Unprotected S** – This medicine is contradicted for use during unprotected s**ual intercourse as it may also lead to birth defects. Antacids – It is recommended not to intake this medicine within a before and after 4 hour period of taking any Antacids. Ledipasvir / Sofosbuvir Medications – Do not take Cimivir L when taking other medications having Ledipasvir and/or Sofosbuvir as their active ingredients. Cimivir L is also contradicted when taken alongside other medications used in the treatment of Chronic Hepatitis C Virus (CHC) infection. Ledipasvir / Sofosbuvir Allergy – Cimivir L is contradicted for use, if you are allergic to Ledipasvir and/or Sofosbuvir which are the active ingredients of Cimivir L. Other Herbal / Dietary Supplements / Prescription Medicines / OTC Medicines – Cimivir L may be contradicted for use when taken with other medications to treat Tuberculosis, Seizures, HIV, Cancer, Cholesterol, Heart ailments and other anti-viral medications. Consult your medical doctor before using Cimivir L by providing a list of any and all existing medications that you are taking to ascertain the safety and use of Cimivir L Side Effects Cimivir L’s active ingredients are ledipasvir & sofosbuvir which may have reported side effects as under: common side effects / symptoms – consult your doctor or medical practitioner if you experience any common side effects or symptoms such as nausea, diarrhea, headache, loss of appetite, lower back pain, side pain, insomnia (sleeplessness) and/or fever. serious side effects / symptoms – discontinue use of Cimivir L and contact your emergency medical center right away if you experience any signs of pale skin, hives, rashes, edema (swelling), mood changes, excessive fatigue, behavior changes, irregular heartbeat, breathing difficulty, breathlessness, swallowing difficulty and/or signs of any infection. unknown side effects / symptoms – Cimivir L may cause other unknown side effects or symptoms not listed here. For complete information, discuss the use of Cimivir L with your doctor or healthcare medical practitioner before use. How Should I Store Cimivir L? Store Cimivir L at room temperature below 86° F (30° C). Keep Cimivir L in its original container. Do not use Cimivir L if the seal over the bottle opening is broken or missing. Keep Cimivir L and all medicines out of the reach of children. Where Can I Buy Cimivir L (Ledipasvir 90 Mg & Sofosbuvir 400 Mg Tablets)? MyMediStore who can ship Cimivir L (Ledipasvir 90 mg & sofosbuvir 400 mg) Tablets to almost any country of the world as per the buyer’s requirement and the buyer’s country’s regulations. Cimivir L (Ledipasvir 90 mg & sofosbuvir 400 mg) Tablets is manufactured by Hetero Healthcare Ltd and is approved by Drug Controller General of India (DCGI) for producing generic Ledipasvir and Sofosbuvir Tablets. Is Cimivir L Tablets Available In India? Cimivir L tablets is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed. MyMediStore facilitates import of cancer medicines on the named patient supply. MyMediStore is facilitator providing input on availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmadabad, Delhi, Bangalore and Pune etc.). finding genuine and reliable source from Canada, Europe, USA and Australia. ensuring 100% transparency. Cimivir L tablets can be made available Mumbai, Kolkata, Hyderabad, Chennai, Ahmadabad, Delhi, Bangalore and Pune and other cities in India” MyMediStore can facilitate the supply of Cimivir L tablets (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable) How Order Will Be Confirmed ? The order will be confirmed only after the receipt of Valid prescription of clinician Import permit if applicable Who Can Produce Generic Ledipasvir And Sofosbuvir Tablets In India? Among the 7 companies licences to produce new hepatitis c drugs the most important onces are Mylan and Natco pharma. Mylan launched a generic sovaldi under trademark name MyHep – these are 400 mg sofosbuvir pills without 90 mg ledipasvir which is present in Ledipasvir and Sofosbuvir Tablets. Natco pharma, on the other hand, had launched both generic sovaldi under the name Hepcinat and generic Ledipasvir and Sofosbuvir Tablets under the name Cimivir L and are selling it in more than 100 developing countries (for example price for 28-pill bottle in Nepal is around $380). Natco Pharma Generic Ledipasvir And Sofosbuvir Tablets Sold Under Trademark Cimivir L Other companies that can produce generic Ledipasvir and Sofosbuvir Tablets are Cipla, Hetero labs, Ranbaxy laboratories, Sequent scientific and strides arcolab. How Can Anyone Buy Generic Ledipasvir And Sofosbuvir Tablets In India? If you are us or European citizen in need of Ledipasvir and Sofosbuvir Tablets for hepatitis c treatment you might have a problem with buying original Ledipasvir and Sofosbuvir Tablets because of the very high costs. This is why ‘hepatitis c turism’ is starting to flourish in India because more and more people are going to India to try to procure generic Ledipasvir and Sofosbuvir Tablets costing only around $1,000. The major problem is how to actually buy it either by going to India or doing it online with a reputable online pharmacy. This is also the reason why we started to work on the manual of how to buy generic Ledipasvir and Sofosbuvir Tablets by making a step-by-step instructions for all patients in need of new hepatitis c drugs. Here are some questions that are fully explained in the manual. I Have A Prescription For Ledipasvir And Sofosbuvir Tablets By Us Doctor But I Can’t Afford The Costs. Can I Just Go With It To India And Buy Generic Ledipasvir And Sofosbuvir Tablets? Getting generic Ledipasvir and Sofosbuvir Tablets is unfortunately as simple as flying to India, going to the first pharmacy and getting generic Ledipasvir and Sofosbuvir Tablets with non-Indian prescription. Patients are advised to know beforehand what they need with them and who to contact. Indian Prescription By Indian Doctor The US or European prescription is not valid in other countries such as India. In order to buy generic Ledipasvir and Sofosbuvir Tablets one must make an appointment with Indian doctor – we enlist specialist who are allowed to write a hepatitis c patient a prescription for either generic Ledipasvir and Sofosbuvir Tablets or generic sovaldi. In order for a doctor to be able to prescribe hepatitis c drugs he or she must confirm the diagnosis of hepatitis c. This includes a series of blood test that need to be performed as well fibroscan. Here is a little scoop from the manual – the paperwork Indian doctors have to fill out in order to write generic hepatitis c prescription includes specific tests that need to be made in order to confirm hepatitis c virus presence in a patient. Here is a tip: most of the Indian doctors will accept test results from us, Europe, Egypt, canada and alike. Bringing all results and blood work you had done with your current doctor to India will not only save you some money but you will avoid the delay that getting appointments for tests and waiting for results might cause. Additionally, be careful that you get a prescription for generic Ledipasvir and Sofosbuvir Tablets from the above stated companies with licences which are approved by fda. Mylan‘s MyHep and Natco’s Cimivir L are reputable and credible medicines. In order to avoid having problems with getting prescription for non-credible drugs we have included a list of doctors and trademark hepatitis c generics in the manual. For More Information visit us our website : mymedistore.com Read the full article

[candicerussell561-blog]

Hepcinat Lp- A Little Info To Know!

Hepatitis C has been one of the most deadly diseases during the earlier times, but with the discovery of medicines like- hepcinat Lp, things have changed a lot. Hepcinat Lp is composed of Sofosbuvir 400 mg + Ledipasvir 90 mg. It comes in a 28 pills bottle, recommended with an intake of one pill per day for total of 84 days (3 bottles) or as recommended by the doctor. The cost for the three bottles is approx $800, however this may vary as per the delivery partner or source you choose for buying the units.

Presence of the generic Sofosbuvir Hep C treatment content in the medicine has made it a magic wand for Hep C treatment. Even though, it isn’t solely responsible for the cure but, it stands as the frontrunner for fight. Generic Sofosbuvir hep C ingredient is basically an interferon-free medication that has the capability to directly inhibit the life of the Hepatitis C virus (HCV) and stops its development.

Sofosbuvir inhibits the growth of the enzyme that helps HCV’s multiplication.

Sofosbuvir also works as a stimulator for stimulating the patient’s immune system for fighting against the invasive HCV virus.

Hepcinat Lp as a drug is recommended for patients suffering from the severe case of HCV, liver disease, or even HIV.

This drug has the ability to drastically improve the treatment and reduce the complication risks.

However, a few side effects such as- headaches, insomnia, stress, itchiness and vomiting are pretty there in this case.

Pregnant women are always recommended to consult a doctor before starting the medication. 

Hepcinat Lp is one of the most highly recommended medicines for the treatment of Hepatitis C with complete efficiency.

[health001stuff-blog]

Buy Online Myhep LVIR - medypharma

Buy Online Myhep LVIR

MyHep LVIR is indicated for the treatment of chronic hepatitis C, a blood-borne infectious disease, as a component of a combination antiviral treatment regimen.

Ledipasvir/sofosbuvir

Is a two drug combination for the treatment of hepatitis C. It is administered as a single daily pill containing 90 mg of the viral NS5A inhibitor ledipasvir and 400 mg of sofosbuvir, a nucleotide inhibitor of the viral RNA polymerase.

Ledipasvir

Ledipasvir is most commonly used in combination with sofosbuvir for treatment in chronic hepatitis C genotype 1 patients. This drug has been tested and shown efficacy in treatment-naive and treatment experienced patients.

Sofosbuvir

Sofosbuvir is used for the treatment of chronic hepatitis C, genotypes 1, 2, 3, and 4, in combination with pegylated interferon and ribavirin, or with ribavirin alone. It is also used in combination with the viral NS5a inhibitor ledipasvir in an interferon-free combination for the treatment of genotype 1 hepatitis C infection. Sofosbuvir is also used in HCV patients with an HIV coinfection.

Facts of MyHep LVIR (Ledipasvir Sofosbuvir Tablets)

Medicine Name: MyHep LVIR Generic Name: Ledipasvir Sofosbuvir Company Name: Mylan Available as (Form & Strength): 400 mg tablets

Uses:

My hep 400mg tablet is used in the treatment of chronic hepatitis C .

How it works:

My hep 400mg tablet is an antiviral drug that belongs to a class of medicines called nucleotide polymerase inhibitors. It inhibits an enzyme RNA polymerase which is essential for viral replication and thus decreases the amount of Hepatitis C virus in the body thereby resulting in less liver damage and improved liver function.   100 blue pill,sildenafil citrate tablets 100mg,blue pill with 100 on it,sildenafil citrate 100mg reviews,cenforce 25,cenforce 100 price,cenforce professional review,does cenforce 100 work,sildenafil citrate 100 mg,sildenafil 100mg online,centurion laboratories viagra,buy sildenafil citrate 100mg,what is cenforce 100,how to use sildenafil citrate tablets,cenforce 200 mg review,citrate tablets,how long does it take for sildenafil to work,what is sildenafil citrate 100mg , cenforce 100 , cenforce 200 , cenforce 150   For more Details :  Buy Online Myhep LVIR  Read the full article

[miajenniblr-blog]

Combinația sa de Sofosbuvir 400 mg și Ledipasvir 90 mg a fost creată special pentru tratamentul genotipului hepatitei C genotipului 1-4. Acest medicament Natco are, de asemenea, efecte similare cu HARVONI în tratarea hepatitei cronice C (CHC).